A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study)

A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study)

<p>Abstract</p> <p>Background</p> <p>Traditional first line regimens containing a non-nucleoside reverse transcriptase inhibitor or protease inhibitor may not be suitable for a subset of antiretroviral-naïve patients such as those with certain co-morbidities, women of c...

Full description

Bibliographic Details
Main Authors: McClernon Daniel, Patel Parul, DeJesus Edwin, LaMarca Anthony, Salvato Patricia, Kumar Princy N, Florance Allison, Shaefer Mark S
Format: Article
Language:English
Published: BMC 2009-04-01
Series:AIDS Research and Therapy
Online Access:http://www.aidsrestherapy.com/content/6/1/3

Similar Items

Similar Items